We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Complement Fixation Endpoint Determined by Spectrophotometer

By LabMedica International staff writers
Posted on 18 Jun 2012
The complement fixation test is an immunological method that can be used to quantify the presence of either a specific antibody or a specific antigen in a patient's serum. More...


The qualification of a positive antibody result is based on a subjective determination of 30% lysis of sheep red blood cells, which can lead to variability in the analysis as the endpoint is observed rather than measured in a machine.

Scientists at the Associated Regional and University Pathologists Institute (ARUP; Salt Lake City, UT, USA) collected two sets of serum samples that had been sent for fungal complement fixation (CF) testing. Eleven samples sent for Coccidioides CF testing were used to assess laboratory technologist endpoint analysis precision and 60 samples sent for Coccidioides, Aspergillus, and Histoplasma mycelia CF testing were used to assess the utility of the spectrophotometric method.

Following the standard CF test, the clear supernatants were placed in round bottomed microplates alongside color standards ranging from 0% to 70% lysis in increments of 10% lysis. The plate was then analyzed by Tecan Rainbow F39200 spectrophotometer (Tecan Group Ltd.; Männedorf, Switzerland). A wavelength of 405 nm was chosen to read all samples as this is a standard wavelength available on common laboratory spectrophotometers and showed a significant optical density above background.

Of the 60 patient serum samples collected, 29 were positive and 31 were negative for CF antibodies against one of the fungal specific antigens by the non-spectrophotometric method. Of the patient serum samples with negative antibody titers, all 31 samples were verified to have negative titers by spectrophotometric analysis and did not vary from the original negative titer value. Of the 29 samples with positive CF antibody titers, 19 samples had titer endpoints that matched, and nine samples only varied endpoints by plus or minus one titer.

The authors concluded that utilizing the spectrophotometric method provided a standard reference by which 30% lysis could be accurately determined and reproduced. An inherent flaw with CF testing is the subjective nature in which the test is read that can lead to poor inter-technologist precision. If titer endpoint is inaccurately assessed, there is the potential for false positive or false negative results. The spectrophotometer method provides an objective means to obtain a titer endpoint, allowing for a reduction in errors caused by human endpoint assessment. The study was published on May 24, 2012, in the Journal of Clinical Laboratory Analysis.

Related Links:
ARUP Institute
Tecan Group Ltd.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
New
Nucleic Acid Purification Instrument
QIAsymphony Connect
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
image Credit: iStock

Tumor Budding Grading May Predict Chemotherapy Benefit in Resected Lung Squamous Cancer

Outcomes after resection for lung squamous cell carcinoma (SqCC) vary substantially, and the uneven benefit of adjuvant chemotherapy complicates postsurgical treatment decisions. Pathologic markers that... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.